HALO 250117 50.00C (HALO250117C50000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

HALO250117C50000

Watchlist

1.86
+1.16+165.71%

15min DelayTrading Jan 6 14:56 ET

1.95High0.70Low

Intraday

5D
Daily

News

Earnings Preview: HALO to Report Financial Results Pre-market on January 08
Moomoo News11:45 ET
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
PR NewswireJan 6 08:30 ET
Express News | Halozyme Announces Takeda Received Regulatory Approval for Hyqvia® 10% Subcutaneous Injection Set With Enhanze® in Japan for Patients With Agammaglobulinemia or Hypogammaglobulinemia
ReutersDec 30, 2024 07:00 ET
Express News | Halozyme Announces argenx's Vydura With Enhanze® Was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
ReutersDec 30, 2024 06:45 ET
Halozyme and Bristol Myers Squibb Secure FDA Nod for Opdivo Qvantig
BenzingaDec 30, 2024 06:34 ET
Express News | Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ With Enhanze® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (Nivolumab) Indications
ReutersDec 30, 2024 06:30 ET

Comments

Meltyy

May 22, 2024 02:41

Clinical Updates💉
⇒ $Larimar Therapeutics (LRMR.US)$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals (CTXR.US)$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics (HALO.US)$ $Bristol-Myers Squibb (BMY.US)$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...

Moomoo AI

Feb 19, 2024 05:59

EPS growth outshines yearly share price gain, hinting at cautious market sentiment. Despite recent sell-off, long-term investors see 16% annual return over five years, suggesting sell-off may be an opportunity for those seeking long-term growth.

Halozyme Therapeutics' (NASDAQ:HALO) Investors Will Be Pleased With Their Impressive 107% Return Over the Last Five Years

Moomoo AI

Dec 25, 2023 05:09

The insider stock selling at Halozyme Therapeutics could raise concerns among shareholders. However, the fact that insiders maintain a considerable amount of shares might suggest some level of alignment between management and smaller shareholders.

Halozyme Therapeutics Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution

Moomoo AI

Nov 28, 2023 04:48

Confidence in Halozyme Therapeutics is suggested due to solid EPS growth and significant insider investment aligning with shareholders' interests.

Should You Be Adding Halozyme Therapeutics (NASDAQ:HALO) To Your Watchlist Today?

Movers and Shakers

May 10, 2023 08:06

Columns Today's Pre-Market Stock Movers: ABNB, RIVN, AFRM, SPCE and More

Gapping up
$Rivian Automotive (RIVN.US)$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings (CELH.US)$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...